MindMaze Home Rehab Triples Training Dose, 84% Self-Guided

MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, has unveiled new real-world evidence from a multi-site program with Vibra Healthcare, presented at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC. The study demonstrates that home-based rehabilitation using MindMotion increased total motor-training dose by a median factor of three compared with usual outpatient therapy alone, with 84% of active training completed independently, without direct therapist supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility, and cognition, alongside high patient satisfaction. These findings build on previously reported inpatient results and support the company's strategy to extend high-dose, high-intensity neurorehabilitation into patients' homes.

The retrospective quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension. Key results included an average of 174 minutes of active training per week, with 84.4% delivered asynchronously. Functional outcomes showed significant pre–post improvements: Barthel Index (+10.4 points), Berg Balance Scale (+10.5 points), SLUMS (+3.4 points), and Timed Up and Go (−8.8 seconds). The full poster, High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence. MindMaze Therapeutics is also preparing for the launch of MindMotion Lite, a tablet-based solution expected by year-end 2026. Recently announced, MindMotion Lite is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers. CEO Zach Henderson commented, “Earlier this year, we showed that MindMaze's high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way. Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic.”